Telomir Pharmaceuticals, Inc. Common Stock

Telomir Pharmaceuticals, Inc., a pre-clinical stage biopharmaceutical company, focuses on developing pharmaceutical products for reversal of oxidative stress, cellular protection, and regulatory mechanism. The company is developing Telomir 1, an oral small molecule metal ion regulator designed to extend telomere caps; maintain cellular balance; and combat oxidative stress that drives aging and disease progression. By modulating essential metal ions such as iron, and copper, Telomir-1 helps protect against age-related conditions, including Progeria, a rare genetic disorder that causes rapid aging in children; Wilson's disease, a genetic disorder leading to toxic copper buildup in the body; and Age-related Macular Degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer's disease. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.